The U.S. Food and Drug Administration (FDA) has officially documented over 1,700 adverse event reports linked to the use of…
Read More
EASD 2026: Tirzepatide Outperforms Semaglutide in Real-World Type 2 Diabetes Analysis
The landscape of metabolic disease management continues to undergo a profound transformation as comparative clinical data accumulates for the newest…
Read More
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
The regulatory landscape surrounding weight-loss medications has reached a critical juncture as the Food and Drug Administration (FDA) reports a…
Read More
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
The rapid proliferation of compounded versions of high-demand GLP-1 receptor agonists has reached a critical inflection point, as the U.S.…
Read More
FDA logs more than 1,700 adverse event reports involving compounded semaglutide and tirzepatide
The regulatory landscape surrounding the booming market for compounded GLP-1 weight-loss medications has reached a critical inflection point, as the…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant reordering in fiscal year 2025, as revealed by the latest "Pharma 50"…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
Tirzepatide Confirmed as Best-in-Class Obesity Therapy Following Landmark SURMOUNT-MAINTAIN Trial Results
Findings from the pivotal Phase III SURMOUNT-MAINTAIN trial, presented at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye,…
Read More
Tirzepatide Shows Promising Adjunct Benefits in Type 1 Diabetes Management, Meta-Analysis Presented at European Congress on Obesity Suggests
The burgeoning field of GLP-1 receptor agonists, celebrated for their transformative impact on obesity and type 2 diabetes (T2D) management,…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s immunotherapy blockbuster, Keytruda (pembrolizumab), maintained its dominant position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording…
Read More
